1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.

Primary Author / Presenter(s)

HP

Helen Parker, PhD

Senior Research Fellow
University of Southampton
Southampton, England, United Kingdom

Co-Author(s)

LC

Louise Carr, PhD

University of Southampton
Southampton, England, United Kingdom
KN

Kevin Norris, PhD

Cardiff University
Cardiff, Wales, United Kingdom
AN

Anna Nilsson-Takeuchi, PhD

University of Southampton
Southampton, England, United Kingdom
HA

Harindra Amarasinghe, PhD

University of Southampton
Southampton, England, United Kingdom
LK

Latha Kadalayil, PhD

University of Southampton
Southampton, England, United Kingdom
ME

Monica Else, MSc

The Institute of Cancer Research
London, England, United Kingdom
AP

Andrew Pettitt

Professor in Haematology
University of Liverpool
Liverpool, England, United Kingdom
Peter Hillmen, MD, PhD

Professor of Experimental Haematology
University of Leeds
St. James University Hospital
Leeds, England, United Kingdom
Anna Schuh, MD, PhD

Professor
Churchill Hospital, Oxford University
Oxford, England, United Kingdom
RW

Renata Walewska, MD

Consultant Haematologist
University Hospitals Dorset
Bournemouth, England, United Kingdom
DB

Duncan Baird, MD

Cardiff University
Cardiff, Wales, United Kingdom
DO

David Oscier, MD

Univeristy Hospitals Dorset
Bournemouth, England, United Kingdom
CP

Chris Pepper, PhD

Brighton and Sussex Medical School
Brighton, England, United Kingdom
DB

Dean Bryant, PhD

Senior Research Fellow
University of Southampton
Southampton, England, United Kingdom
JG

Jane Gibson, PhD

University of Southampton
Southampton, England, United Kingdom
JS

Jonathan C. Strefford, PhD

Head of School, Cancer Sciences
University of Southampton
Southampton, England, United Kingdom